• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

    29.03 -0.97 (-3.23%)
    Streaming Delayed Price Updated: 10:33 AM EST, Mar 3, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 150,453
    Open 28.72
    Bid (Size) 28.95 (300)
    Ask (Size) 29.06 (200)
    Prev. Close 30.00
    Today's Range 28.72 - 29.90
    52wk Range 14.40 - 31.31
    Shares Outstanding 66,344,236
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +7.5%
    +7.5%
    1 Month
    +17.7%
    +17.7%
    3 Month
    +12.0%
    +12.0%
    6 Month
    +31.6%
    +31.6%
    1 Year
    +50.0%
    +50.0%

    More News

    Read More
    News headline image
    CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big Pharma’s Dupixent ↗
    Via Stocktwits
    Topics Earnings
    News headline image
    Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Celldex to Present at Upcoming Investor Conferences
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Celldex Therapeutics SVPs Engage In Heavy Transactions ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday? ↗
    Via Benzinga
    News headline image
    Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Celldex to Present at Upcoming Investor Conferences
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Analyst Expectations For Celldex Therapeutics's Future ↗
    Via Benzinga
    News headline image
    Technical Breakout Setup for CELLDEX THERAPEUTICS INC (NASDAQ:CLDX) ↗
    Via Chartmill
    News headline image
    5 Analysts Assess Celldex Therapeutics: What You Need To Know ↗
    Via Benzinga
    News headline image
    Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
    Via Benzinga
    News headline image
    Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short ↗
    Via Benzinga
    News headline image
    What Analysts Are Saying About Celldex Therapeutics Stock ↗
    Via Benzinga
    News headline image
    La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
    Via Benzinga

    Frequently Asked Questions

    Is Celldex Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Celldex Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Celldex Therapeutics, Inc. - Common Stock trade on?
    Celldex Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Celldex Therapeutics, Inc. - Common Stock?
    The ticker symbol for Celldex Therapeutics, Inc. - Common Stock is CLDX on the Nasdaq Stock Market
    What is the current price of Celldex Therapeutics, Inc. - Common Stock?
    The current price of Celldex Therapeutics, Inc. - Common Stock is 29.03
    When was Celldex Therapeutics, Inc. - Common Stock last traded?
    The last trade of Celldex Therapeutics, Inc. - Common Stock was at 03/03/26 10:33 AM ET
    What is the market capitalization of Celldex Therapeutics, Inc. - Common Stock?
    The market capitalization of Celldex Therapeutics, Inc. - Common Stock is 1.93B
    How many shares of Celldex Therapeutics, Inc. - Common Stock are outstanding?
    Celldex Therapeutics, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.